Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Steroids + TKI with Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive ALL
NCT04530565Phase 3Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jan 2021
- Primary completion
- Jul 2028
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 3
01
Overview
A Phase 3 trial of blinatumomab in acute lymphoblastic leukemia (ALL), sponsored by National Cancer Institute. Started Jan 2021; status: active, not recruiting.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT04530565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04530565.